Mechanisms of macrolide resistance in clinical pneumococcal isolates in a university hospital, Ankara, Turkey

Journal of Chemotherapy

Volumn 17, Issue 1, 2005, Pages 31-35

  Sener, B ^a   Koseoglu O ^a   Gur D ^a   Bryskier, A ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b SANOFI   (France)

Author keywords

Macrolide resistance phenotypes and genotypes; Streptococcus pneumoniae

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; ERYTHROMYCIN; MACROLIDE; PENICILLIN G; TELITHROMYCIN;

AGAR MEDIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BIOASSAY; CONTROLLED STUDY; ERM(B) GENE; GENOTYPE; GRAM POSITIVE BACTERIUM; MEF(A) GENE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; MOLECULAR GENETICS; MUTAGENESIS; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; STREPTOCOCCUS PNEUMONIAE;

EID: 16244405286     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.1.31     Document Type: Article

References (26)

1. Leclerq R, Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002;46: 2727-34.
2. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995;39: 577-85.
3. Sutcliffe JA, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996;40: 1817-24.
4. Inoue M, Lee NY, Hong SW, Lee K, Felmingham D. PROTEKT 1999-2000: a multicentre study of the antibiotic susceptibility of respiratory tract pathogens in Hong Kong, Japan and South Korea. Int J Antimicrob Agents 2004;23: 44-51.
5. Tait-Kamradt A, Davies T, Appelbaum PC et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000;44: 3395-401.
6. Sener B, Günalp A. Trends in antimicrobial resistance of Streptococcus pneumoniae in children in a Turkish hospital. J Antimicrob Chemother 1998;42: 381-84.
7. Gür D, Güçiz B, Hasçelik G et al. Streptococcus pneumoniae penicillin resistance in Turkey. J Chemother 2001;13: 541-45.
8. Sener B, Köseoglu Ö. Comparative in-vitro activity of antiribosomal agents on penicillin susceptible and resistant Streptococcus pneumoniae in relation to their resistance phenotypes. Int J Antimicrob Agents 2004;24: 39-42.
9. th. Edition: Approved standard M7-A5. NCCLS, Wayne, PA, USA.
10. Smith AM, Klugman KP, Coffey TJ, Spratt BG. Genetic diversity of penicillin-binding protein 2B and 2X genes from Streptococcus pneumoniae in South Africa. Antimicrob Agents Chemother 1993;37: 1938-1944.
11. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 1996;40: 2562-2566.
12. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003;47: 1867-74.
13. Pihlajamaki M, Jalava J, Huovinen P, Kotilainen P, Finnish Study Group for Antimicrobial Resistance. Antimicrobial resistance of invasive pneumococci in Finland in 1999-2000. Antimicrob Agents Chemother 2003;47: 1832-35.
14. Kozlov RS, Bogdanovitch TM, Appelbaum PC et al. Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia. Antimicrob Agents Chemother 2002;46: 2963-68.
15. Baquero F, Garcia Rodriguez JA, Garcia de Lomas J, Aguilar L & the Spanish Surveillance Group for Respiratory Tract Pathogens. Antimicrobial resistance of 1113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. Antimicrob Agents Chemother 1999;43: 357-359.
16. Oster P, Zanchi A, Cresti S. Patterns of macrolide resistance determinants among community acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates. Antimicrob Agents Chemother 1999;43: 2510-12.
17. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 2004;48: 56-65.
18. Song JH, Chang HH, Suh JY et al. Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP). J Antimicrob Chemother 2004;53: 457-63.
19. Fitoussi F, Doit C, Geslin P, Brahimi N, Bingen E. Mechanisms of macrolide resistance in clinical pneumococcal isolates in France. Antimicrob Agents Chemother 2001;45: 636-38.
20. Baquero, F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption. Journal of Chemotherapy 1999;11 (Suppl. 1), 35-43.
21. Reinert RR, Wild A, Appelbaum P, Lutticken R, Cil MY, Al-Lahham A. Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany. Antimicrob Agents Chemother 2003;47: 2319-22.
22. Farrell DJ, Douthwaite S, Morrissey I et al. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob Agents Chemother 2003;47: 1777-83.
23. Shortridge VD, Doern GV, Brueggemann AB, Beyer JM, Flamm RK. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 1999;29: 1186-88.
24. Morosini MI, Canton R, Loza E et al. In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms. Antimicrob Agents Chemother 2001;45: 2427-31.
25. Douthwaite S, Champney WS. Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site. J Antimicrob Chemother 2001;48: (Suppl T1), 1-8.
26. Sutcliffe J. Resistance to macrolides mediated by efflux mechanisms. Curr Opin Invest Drugs 1999;1: 403-12.